Industry Strength Score
43/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NYXOAH SA (NYXH) Stock Price & Overview
NASDAQ:NYXH • BE0974358906
Current stock price
3.01 USD
+0.01 (+0.33%)
At close:
2.91 USD
-0.1 (-3.32%)
Pre-Market:
The current stock price of NYXH is 3.01 USD. Today NYXH is up by 0.33%. In the past month the price increased by 7.89%. In the past year, price decreased by -50.66%.
NYXH Key Statistics
52-Week Range2.76 - 8.64
Current NYXH stock price positioned within its 52-week range.
1-Month Range2.79 - 3.64
Current NYXH stock price positioned within its 1-month range.
- Market Cap
- 131.417M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.76
- Dividend Yield
- N/A
NYXH Stock Performance
Today
+0.33%
1 Week
-6.52%
1 Month
+7.89%
3 Months
-36.63%
Longer-term
6 Months -42.00%
1 Year -50.66%
2 Years -70.90%
3 Years -62.79%
5 Years N/A
10 Years N/A
NYXH Stock Chart
NYXH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NYXH. When comparing the yearly performance of all stocks, NYXH is a bad performer in the overall market: 94.06% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
NYXH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NYXH. Both the profitability and financial health of NYXH have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NYXH Earnings
On March 19, 2026 NYXH reported an EPS of -0.59 and a revenue of 5.64M. The company missed EPS expectations (-5.5% surprise) and beat revenue expectations (20.65% surprise).
Next Earnings DateMay 12, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported-€0.59
Revenue Reported5.644M
EPS Surprise -5.50%
Revenue Surprise 20.65%
NYXH Forecast & Estimates
14 analysts have analysed NYXH and the average price target is 9.82 USD. This implies a price increase of 226.27% is expected in the next year compared to the current price of 3.01.
For the next year, analysts expect an EPS growth of 18.35% and a revenue growth 252.82% for NYXH
Analysts
Analysts81.43
Price Target9.82 (226.25%)
EPS Next Y18.35%
Revenue Next Year252.82%
NYXH Financial Highlights
Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -2.76. The EPS decreased by -31.24% compared to the year before.
Income Statements
Revenue(TTM)10.02M
Net Income(TTM)-90.08M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.04% | ||
| ROE | -183.36% | ||
| Debt/Equity | 0.37 |
Chartmill High Growth Momentum
EPS Q2Q%-26.57%
Sales Q2Q%346.87%
EPS 1Y (TTM)-31.24%
Revenue 1Y (TTM)121.63%
NYXH Ownership
Ownership
Inst Owners21.41%
Shares43.66M
Float27.49M
Ins Owners19.69%
Short Float %1.18%
Short Ratio5.94
NYXH Industry Overview
NYXH operates in the Health Care Equipment sub-industry within the Health Care sector. This group contains 35 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
70/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
40%
Outperformed 40% of sub-industries
3 Month Rank
33%
Outperformed 33% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 35
- New Highs
- 5.7%
- New Lows
- 11.4%
- Average ROE
- 9.8%
- Average Profit Margin
- 9.8%
- Average Operating Margin
- 14.8%
- Average P/E
- 15.9
- Average Fwd P/E
- 14.0
- Average Debt/Equity
- 0.6
NYXH Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 40.01 | 165.737B | ||
| ABT | ABBOTT LABORATORIES | 14.94 | 163.098B | ||
| SYK | STRYKER CORP | 21.26 | 123.101B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.81 | 86.867B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.39 | 47.438B | ||
| IDXX | IDEXX LABORATORIES INC | 38.38 | 45.134B | ||
| BDX | BECTON DICKINSON AND CO | 10.95 | 42.574B | ||
| RMD | RESMED INC | 17.69 | 31.633B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.26 | 31.256B | ||
| DXCM | DEXCOM INC | 23.33 | 22.83B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.76 | 16.028B | ||
| PEN | PENUMBRA INC | 63.95 | 12.818B | ||
| PODD | INSULET CORP | 28.2 | 12.666B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NYXH
Company Profile
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Company Info
IPO: 2020-09-18
NYXOAH SA
Rue Edouard Belin 12
Mont-Saint-Guibert BRABANT-WALLON BE
CEO: Olivier Taelman
Employees: 184
Phone: 3226121755
NYXOAH SA / NYXH FAQ
What does NYXH do?
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
What is the stock price of NYXOAH SA today?
The current stock price of NYXH is 3.01 USD. The price increased by 0.33% in the last trading session.
Does NYXH stock pay dividends?
NYXH does not pay a dividend.
What is the ChartMill rating of NYXOAH SA stock?
NYXH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is NYXOAH SA (NYXH) stock traded?
NYXH stock is listed on the Nasdaq exchange.
What is the market capitalization of NYXH stock?
NYXOAH SA (NYXH) has a market capitalization of 131.42M USD. This makes NYXH a Micro Cap stock.